• Ronald C. Walker
  • Laurie B. Jones-Jackson
  • Aaron C. Jessop
  • Dominique Delbeke


The National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database has demonstrated an increase in annual incidence of cutaneous melanoma of 619% and an increase in annual mortality of 165% from 1950 to 2000. In 2004, an estimated 55,000 Americans were newly diagnosed with cutaneous melanoma, and approximately 7,900 died from this disease. Of all cancers in the United States, cutaneous melanoma ranks fifth in incidence among men and seventh among women. It is the most common cancer in women aged 20–29 and the second leading cause of lost productive years.


Single Photon Emission Compute Tomography Sentinel Lymph Node National Comprehensive Cancer Network Cutaneous Melanoma Maximal Intensity Projection Image 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. New Engl J Med 2004;351:998–1012.CrossRefPubMedGoogle Scholar
  2. 2.
    Domingo-Domenech J, Molina R, Castel T, Montagut C, Puig S, Conill C, Martí R, Vera M, Auge JM, Malvehy J, Grau JJ, Gascon P, Mellado B. Serum protein S-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon – comparison with tyrosinase re-PCR. Oncology 2005;68:341–349.CrossRefPubMedGoogle Scholar
  3. 3.
    Garbe C, Leiter, U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B. Diagnostic value and prognostic significance of protein S-100β, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase charin reaction in the follow-up of high-risk melanoma patients. Cancer 2003;97:1737–1745.CrossRefPubMedGoogle Scholar
  4. 4.
    Wascher RA, Morton DL, Kuo C, Elashoff RM, Wang H-J, Gerami M, Hoon DSB. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol 2003;21:2558–2563.CrossRefPubMedGoogle Scholar
  5. 5.
    Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635–3648.PubMedGoogle Scholar
  6. 6.
    Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C-H, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976–983.PubMedGoogle Scholar
  7. 7.
    Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang H-J, for the MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307–1317. Erratum in: N Engl J Med 2006;355:1944.Google Scholar
  8. 8.
    Alazraki N, Glass EC, Castronovo F, Valdes Olmos RA, Podoloff D. Society of Nuclear Medicine procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness. J Nucl Med 2002;93:1414–1418.Google Scholar
  9. 9.
    Belhocine TZ, Scott AM, Evan-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006;47:957–967.PubMedGoogle Scholar
  10. 10.
    Even-Sapir E, Lerman H, Lievshitz G, Khafif A, Fliss DM, Schwart A, Gur E, Skornick Y, Schneebaum S. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med 2003;44:1413–1420.PubMedGoogle Scholar
  11. 11.
    Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:237–242.CrossRefPubMedGoogle Scholar
  12. 12.
    Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 2004;34:242–253.CrossRefPubMedGoogle Scholar
  13. 13.
    Balch CM, Soong S, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu P-Y, Lyman JH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622–3634.PubMedGoogle Scholar
  14. 14.
    Garbe C, Paul A, Kohler-Späth H. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J Clin Oncol 2003;21:520–529.CrossRefPubMedGoogle Scholar
  15. 15.
    Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: State of the art 2006. Melanoma Res 2007;17:117–127.CrossRefPubMedGoogle Scholar
  16. 16.
    Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, Phelps ME, Czernin J, Gambhir SS. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000;44:153–167.PubMedGoogle Scholar
  17. 17.
    Bastiaannet E, Oyen WJG, Meijer S, Hoekstra OS, Wobbes T, Jager PL, Hoekstra HL. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg 2006;93:243–249.CrossRefPubMedGoogle Scholar
  18. 18.
    Strobel K, Dummer R, Husarik D, Lago MP, Hany MF, Steinert HC. High-risk melanoma: Accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007;244:566–674.CrossRefPubMedGoogle Scholar
  19. 19.
    Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, Roedel R, Strunk H, Bieber T, Biersack H-J, Tüting T. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: Experience with 250 consecutive patients. J Clin Oncol 2006;24:1178–1187.CrossRefPubMedGoogle Scholar
  20. 20.
    Kato K, Kubota T, Ikeda M, Tadokoro M, Abe S, Nakano S, Nishino M, Kobayashi H, Ishigaki T. Low efficacy of 18F-FDG PET for detection of uveal malignant melanoma compared with 123I-IMP SPECT. J Nucl Med 2006;47:404–409.PubMedGoogle Scholar
  21. 21.
    Reddy S, Kurli M, Tena LB, Finger PT. PET/CT imaging: Detection of choroidal melanoma. Br J Ophthalmol 2005;89:1265–1269.CrossRefPubMedGoogle Scholar
  22. 22.
    Finger PT, Kurli M, Reddy S, Tena LB, Pavlick AC. Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 2005;89:1270–1274.CrossRefPubMedGoogle Scholar
  23. 23.
    Lane KA, Bilyk JR. Preliminary study of positron emission tomography in the detection and management of orbital malignancy. Ophthal plast Reconstr Surg 2006;22:361–365.CrossRefPubMedGoogle Scholar
  24. 24.
  25. 25.
    Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman E, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF. Recommendations for the Use of FDG(fluorine-18, (2-[18F]Fluoro-2-deoxy-D-glucose) positron emission tomography in oncology. J Nucl Med 2008;49:480–508.CrossRefPubMedGoogle Scholar
  26. 26.
    Chiles C, Woodard PK, Gutierrez FR, Link KM. Metastatic involvement of the heart and pericardium: CT and MR imaging. Radiographics 2001;21:439–449.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Ronald C. Walker
    • 1
  • Laurie B. Jones-Jackson
    • 1
  • Aaron C. Jessop
    • 1
  • Dominique Delbeke
    • 1
  1. 1.Department of Radiology and Radiological SciencesVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations